Published in Oncol Rep on August 01, 2005
Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia (2010) 1.58
Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett (2008) 1.20
DNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep (2013) 1.00
DNMT3B promoter polymorphism and risk of gastric cancer. Dig Dis Sci (2009) 0.97
Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer. Int J Colorectal Dis (2011) 0.93
Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet-gene interactions and promoter CpG island hypermethylation in colorectal cancer. Cancer Causes Control (2010) 0.85
The DNMT3B -579 G>T promoter polymorphism and risk of lung cancer. Exp Ther Med (2011) 0.82
Systematic evaluation of cancer risk associated with DNMT3B polymorphisms. J Cancer Res Clin Oncol (2014) 0.82
Two-stage case-control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk. Breast Cancer Res Treat (2009) 0.82
The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients. Iran J Med Sci (2014) 0.80
Polymorphism of DNA methyltransferase 3B -149C/T and cancer risk: a meta-analysis. Med Oncol (2014) 0.80
Influence of DNMT genotype on global and site specific DNA methylation patterns in neonates and pregnant women. PLoS One (2013) 0.78
Associations of ChREBP and Global DNA Methylation with Genetic and Environmental Factors in Chinese Healthy Adults. PLoS One (2016) 0.78
Leukocyte DNA methylation and colorectal cancer among male smokers. World J Gastrointest Oncol (2012) 0.78
Association of DNMT3B -283 T > C and -579 G > T polymorphisms with decreased cancer risk: evidence from a meta-analysis. Int J Clin Exp Med (2015) 0.77
The -149C>T polymorphism of DNMT3B is not associated with colorectal cancer risk: Evidence from a meta-analysis based on case-control studies. Exp Ther Med (2012) 0.76
Changes in DNA methylation patterns and repetitive sequences in blood lymphocytes of aged horses. Age (Dordr) (2013) 0.75
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol (2012) 2.70
Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol (2010) 2.48
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol (2012) 2.28
"Complete transurethral resection of bladder tumor": are the guidelines being followed? Urology (2009) 2.16
Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol (2009) 2.09
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int (2007) 1.72
Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol (2008) 1.64
Comparative validation of nomograms predicting clinically insignificant prostate cancer. Urology (2013) 1.49
Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology (2006) 1.49
Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology (2009) 1.49
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. Eur Urol (2012) 1.42
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41
Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int (2010) 1.40
Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer (2006) 1.38
Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.29
Treatment of local breast carcinoma in Florida: the role of the distance to radiation therapy facilities. Cancer (2006) 1.28
Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol (2004) 1.23
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
Small cell carcinoma of the head and neck: the university of Miami experience. Int J Radiat Oncol Biol Phys (2008) 1.21
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat (2013) 1.16
Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. Eur Urol (2009) 1.15
Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. J Clin Oncol (2002) 1.10
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit (2009) 1.05
Cognitive-behavioral therapy to promote smoking cessation among African American smokers: a randomized clinical trial. J Consult Clin Psychol (2010) 1.03
Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol (2007) 1.02
Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep (2004) 1.01
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res (2009) 1.00
Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int (2008) 0.98
Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation. Cancer (2012) 0.97
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 0.96
Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology (2008) 0.96
HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer (2007) 0.95
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer (2010) 0.93
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Intraoperative cell salvage during radical cystectomy does not affect long-term survival. Urology (2007) 0.93
Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology (2011) 0.92
Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology (2005) 0.91
Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int (2007) 0.91
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res (2012) 0.91
Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol (2011) 0.91
Phase II clinical trials in oncology: strengths and limitations of two-stage designs. Cancer Invest (2006) 0.90
Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int (2012) 0.90
Spontaneous rupture of bladder presenting as peritonitis. N Z Med J (2002) 0.90
Current concepts in the management of adrenal incidentalomas. Urol Ann (2012) 0.89
Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology (2004) 0.89
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology (2009) 0.88
Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer (2011) 0.88
The role of liver transplantation techniques in the surgical management of advanced renal urothelial carcinoma with or without inferior vena cava thrombus. Int Braz J Urol (2009) 0.87
Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models. BJU Int (2012) 0.87
Does body mass index affect outcome after reconstruction of orthotopic neobladder? Urology (2007) 0.87
Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia. Cancer (2010) 0.87
Clinically significant Gleason sum upgrade: external validation and head-to-head comparison of the existing nomograms. Cancer (2011) 0.86
Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. Urology (2010) 0.86
CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers. Appl Immunohistochem Mol Morphol (2012) 0.85
Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors. BJU Int (2004) 0.85
Synchronous panniculectomy with stomal revision for obese patients with stomal stenosis and retraction. BJU Int (2009) 0.85
Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. Clin Breast Cancer (2013) 0.84
Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol (2012) 0.84
Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. World J Urol (2011) 0.84
Surgical margin status does not affect overall survival following radical prostatectomy: a single institution experience with expectant management. Can J Urol (2012) 0.83
Pathologic evaluation of non-neoplastic renal parenchyma in partial nephrectomy specimens. World J Urol (2011) 0.83
Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion. Indian J Urol (2012) 0.83
Evaluation of analgesic requirements and postoperative recovery after radical retropubic prostatectomy using long-acting spinal anesthesia. Urology (2005) 0.83
Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol (2012) 0.83
Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther (2003) 0.83
Adrenocortical carcinoma with tumor thrombus in the right hepatic vein. Int J Urol (2006) 0.83
Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods. Anticancer Res (2013) 0.82
Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol (2002) 0.82
Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer. Am J Ther (2012) 0.82
The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons. Neurosci Res (2011) 0.82
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. Carcinogenesis (2011) 0.82
Renal cell carcinoma with solitary metastasis to the bladder: mode of spread and prognosis. Can J Urol (2012) 0.82
Neither alpha-blocker therapy nor cystography is required before early catheter removal after radical prostatectomy. BJU Int (2005) 0.81
Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted? BJU Int (2005) 0.81
Basal cell carcinoma of the prostate: current concepts. BJU Int (2007) 0.80
Epigenetics application in the diagnosis and treatment of bladder cancer. Can J Urol (2015) 0.80
Total prostatectomy and lymph node dissection may be done safely without pelvic drainage: an extended experience of over 600 cases. Can J Urol (2009) 0.80
Is the incidence of uretero-intestinal anastomotic stricture increased in patients undergoing radical cystectomy with previous pelvic radiation? BJU Int (2009) 0.80
Detection of tumor cells in body cavity fluids by flow cytometric and immunocytochemical analysis. Diagn Cytopathol (2006) 0.80
Higher chest wall dose results in improved locoregional outcome in patients receiving postmastectomy radiation. Int J Radiat Oncol Biol Phys (2011) 0.80
Management of neobladder-vaginal fistula and stress incontinence following radical cystectomy in women: a review. World J Urol (2005) 0.80
Pathological findings at radical prostatectomy in patients initially managed by active surveillance: a comparative analysis. Prostate (2012) 0.79
A pelvic drain can often be avoided after radical retropubic prostatectomy--an update in 552 cases. Eur Urol (2006) 0.79
Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer. Can J Urol (2015) 0.79